Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
Bensimon AG, Zhong Y, Swami U, Briggs A, Young J, Feng Y, Song Y, Signorovitch J, Adejoro O, Chakravarty A, Chen M, Perini RF, Geynisman DM.
Bensimon AG, et al. Among authors: song y.
Curr Med Res Opin. 2020 Sep;36(9):1507-1517. doi: 10.1080/03007995.2020.1799771. Epub 2020 Aug 8.
Curr Med Res Opin. 2020.
PMID: 32697113